Leukemia Clinical Trials in Los Angeles

Showing 1061-1080 of 1,166 trials

Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia

NCT00006084

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody in treating patients who have acute myelogenous leukemia that did not respond to standard treatment given in clinical trial PDL 195-301.

Leukemia

Jonsson Comprehensive Cancer CenterStarted Feb 2001

Los Angeles, California, United States

UNKNOWNPhase 2< 1 mile

Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy

NCT00003634

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether giving monoclonal antibody therapy is more effective than a placebo in treating patients with ovarian epithelial, fallopian tube, or peritoneal cancer who have responded to surgery and chemotherapy. PURPOSE: Randomized phase II trial to study the effectiveness of monoclonal antibody therapy in treating patients with residual disease from stage III or stage IV ovarian epithelial, fallopian tube, or peritoneal cancer following surgery and chemotherapy.

Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer

AltaRex400 participantsStarted Apr 1998

Berkeley, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +43 more locations

Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia

Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy

Leukemia Trials in Other Cities

Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia

Study of Bronchodilation Effects of Cetirizine

Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC

Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas

Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia

Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)

Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

Other Conditions in Los Angeles